Learn how a new genetic therapy could transform treatment for rare ALS—keep reading for remarkable patient outcomes.

Delray Beach, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching US$2.51 ...

Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, ...

The Oligonucleotide Therapeutics and Delivery conference reveals the latest in oligonucleotide discovery and delivery, with presentations on targeted delivery mechanisms, oligonucleotide ...

Clinics across the U.S. are claiming to treat cancer, Lyme disease, and other bacterial and viral infections with "supportive oligonucleotide therapy (SOT)" -- a treatment lacking both data and ...

PepGen to focus on development of DM1 programme following 10 mg/kg PGN-EDO51 update: Boston Friday, May 30, 2025, 14:00 Hrs [IST] PepGen Inc, a clinical-stage biotechnology compan ...

A biochemical breakthrough using simple carbon atoms, by Ken Yamada, Ph.D., and Anastasia Khvorova, Ph.D., has dramatically improved the stability and efficacy of a potential oligonucleotide ...

The Chromatographic Society and RSC Separation Science Group are pleased to announce, Analytical Horizons in Oligonucleotide Separation Science. The Spring Symposium will be held on Wednesday 7th May ...